A Phase III Study of the Safety and Efficacy of Ferumoxytol (Compared With Oral Iron) as an Iron Replacement Therapy in Hemodialysis Patients Who Are Receiving Supplemental EPO Therapy

NCT00233597 Phase 3 COMPLETED

The study will evaluate the safety and efficacy of a new intravenously administered iron drug to treat anemia in patients on hemodialysis.

Details

Lead sponsor	AMAG Pharmaceuticals, Inc.
Phase	Phase 3
Status	COMPLETED
Enrolment	230
Start date	2004-08
Completion	2007-03

Conditions

• Anemia

Interventions

• ferumoxytol or oral iron

Primary outcomes

• The mean change in hemoglobin from baseline.

Countries

United States